Auditory results after vestibular nerve section and intratympanic gentamicin for Ménière's disease.
OBJECTIVE
Hearing loss is a possible complication of vestibular neurectomy and intratympanic gentamicin administration in Ménière's disease. The aim of this study was to compare the incidence of this complication with the two treatments.


METHODS
Retrospective review.


METHODS
Tertiary referral center.


METHODS
The initial study population reviewed consisted of 24 patients receiving gentamicin injections and 209 patients undergoing vestibular nerve section. Comparison of data was performed among all 24 intratympanic gentamicin patients and the last 24 vestibular neurectomy patients operated on via the retrosigmoid approach.


METHODS
Intratympanic gentamicin administration (26-156 mg) and retrosigmoid vestibular neurectomy.


METHODS
Auditory and vertigo results were evaluated according to the American Academy of Otolaryngology 1995 criteria.


RESULTS
The mean preoperative pure-tone average for patients undergoing vestibular nerve section was 48.5 dB, with a speech discrimination score of 85%. In these patients, the postoperative pure-tone average was 50.3 dB, and the speech discrimination score was 82%. Patients undergoing gentamicin injection had a mean pretreatment pure-tone average of 50.1 dB and a speech discrimination score of 87%. The posttreatment pure-tone average and discrimination score for the gentamicin group were 74.7 dB and 65%, respectively. The amount of postprocedure hearing loss was significantly greater in the gentamicin group (p = 0.03). Excellent control of vertigo (classes A and B) was obtained in 95.8% of the patients treated with vestibular nerve section and in 75% of the patients in the gentamicin group.


CONCLUSIONS
Gentamicin administration and vestibular neurectomy are both effective for relieving vertigo in Ménière's disease. The incidence of hearing loss is significantly higher after gentamicin injection.
Colletti
Vittorio
V
ENT Department, University of Verona, Verona, Italy. vittoriocolletti@yahoo.com
Carner
Marco
M
Colletti
Liliana
L
D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001301:Audiometry, Pure-Tone / Q000379:methods*; D005260:Female; D005839:Gentamicins / Q000008:administration & dosage / Q000627:therapeutic use*; D006319:Hearing Loss, Sensorineural / Q000175:diagnosis* / Q000453:epidemiology; D006801:Humans; D007267:Injections; D008297:Male; D008575:Meniere Disease / Q000188:drug therapy* / Q000453:epidemiology / Q000601:surgery*; D008875:Middle Aged; D013506:Otologic Surgical Procedures / Q000379:methods*; D011184:Postoperative Period; D012189:Retrospective Studies; D012720:Severity of Illness Index; D014432:Tympanic Membrane; D014725:Vestibular Nerve / Q000601:surgery*
D000900:Anti-Bacterial Agents; D005839:Gentamicins